Suchergebnisse - (Subject:"Siltuximab")

PubPharm (20)

1

Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease

enthalten in: Blood advances | 2022

von van Rhee, F. | Rosenthal, A. | Kanhai, K. | +4

2

Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID) : a factorial, randomised, controlled trial

enthalten in: The Lancet. Respiratory medicine | 2021

von Declercq, J. | Van Damme, K. | De Leeuw, E. | +40

CommentIn: Lancet Respir Med. 2021 Dec;9(12):1353-1354. - PMID 34756179

3

Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab

enthalten in: British journal of haematology | 2021

von van Rhee, F. | Rossi, J. | Simpson, D. | +10

4

Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease

enthalten in: American journal of hematology | 2020

von Fajgenbaum, D. | Wu, D. | Goodman, A. | +21

5

Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease : a prespecified, open-label, extension analysis of two trials

enthalten in: The Lancet. Haematology | 2020

von van Rhee, F. | Casper, C. | Voorhees, P. | +4

6

Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2019

von Brighton, T. | Khot, A. | Harrison, S. | +15

7

Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease : secondary analyses of phase II clinical trial data

enthalten in: British journal of haematology | 2019

von Morra, D. | Pierson, S. | Shilling, D. | +6

8

Deriving health utility values from a randomized, double-blind, placebo-controlled trial of siltuximab in subjects with multicentric Castleman's disease

enthalten in: Current medical research and opinion | 2016

von Vernon, M. | Robinson, D. | Trundell, D. | +3

9

A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease

enthalten in: Oncotarget | 2015

von van Rhee, F. | Casper, C. | Voorhees, P. | +7

10

Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2015

von Casper, C. | Chaturvedi, S. | Munshi, N. | +9